EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Emerging therapies and real-world application of metabolic dysfunction-associated steatotic liver disease treatment

Hee Yeon Kim, Mary E Rinella

Clinical and Molecular Hepatology · 01.07.2025 · 31 (3) · 753-770

DOI: 10.3350/cmh.2025.0083 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 01.07.2025. Verfasst von Hee Yeon Kim und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction-associated steatotic liver disease, formerly referred to as non-alcoholic fatty liver disease, is the most common liver disease in Western countries and has emerged as the leading indication for liver transplantation. Metabolic dysfunction-associated steatohepatitis (MASH), a more advanced stage, carries a high risk of progression to liver fibrosis, cirrhosis, liver failure, and hepatocellular carcinoma. Until recently, lifestyle intervention remained the mainstay of MASH management, with no pharmacological treatments specifically approved. However, advances in understanding its pathophysiological mechanisms have fueled numerous clinical trials, culminating in the Food and Drug Administration’s (FDA) approval of resmetirom as the first treatment for MASH in 2024. Additionally, many investigational drugs are nearing FDA approval or progressing through late-stage clinical trials. This review examines the current therapeutic landscape, highlights strategies for identifying patients suitable for liver-directed therapies in real-world settings, and discusses the challenges that remain.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseHumansLiver CirrhosisPropionatesChalcones

Stichwörter der Autor:innen

Clinical trialsMetabolic dysfunction-associated steatotic liver diseasePharmacological treatmentsSteatohepatitis

Substanzen

2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acidPropionatesChalcones

Autor:innen und Institutionen

  • Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Division of Gastroenterology, Hepatology and Nutrition, University of Chicago Pritzker School of Medicine, Chicago, IL, USA.

Zitieren

APA

Kim, H. Y., & Rinella, M. E. (2025). Emerging therapies and real-world application of metabolic dysfunction-associated steatotic liver disease treatment. Clinical and Molecular Hepatology, 31(3), 753-770. https://doi.org/10.3350/cmh.2025.0083

Vancouver

Kim HY, Rinella ME. Emerging therapies and real-world application of metabolic dysfunction-associated steatotic liver disease treatment. Clinical and Molecular Hepatology. 2025;31(3):753-770. doi:10.3350/cmh.2025.0083

BibTeX
@article{Kim2025,
  author = {Kim, Hee Yeon and Rinella, Mary E},
  title = {Emerging therapies and real-world application of metabolic dysfunction-associated steatotic liver disease treatment},
  journal = {Clinical and Molecular Hepatology},
  year = {2025},
  volume = {31},
  number = {3},
  pages = {753--770},
  doi = {10.3350/cmh.2025.0083}
}
Kostenlos starten →